SCHEMBL1361161

SCHEMBL1361161

OCC(O)CN1CCNCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.64
ATM Q13315 1/20 0.64
SMN1; SMN2 Q16637 2/20 0.55
RAD52 P43351 1/20 0.47
ADRA2A P08913 1/20 0.46
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
BAX Q07812 1/20 0.44
POLB P06746 2/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
IDO1 P14902 1/20 0.42
USP2 O75604 1/20 0.41
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4400918 1.00 MAPT (0.64) MAPTATMSMN1; SMN2RAD52ADRA2A
SCHEMBL16908299 1.00 MAPT (0.64) MAPTATMSMN1; SMN2RAD52ADRA2A
SCHEMBL15553304 0.98 MAPT (0.61) MAPTATMSMN1; SMN2RAD52ADRA2A
SCHEMBL14034485 0.98 MAPT (0.61) MAPTATMSMN1; SMN2RAD52ADRA2A
SCHEMBL10696876 0.98 MAPT (0.61) MAPTATMSMN1; SMN2RAD52ADRA2A
SCHEMBL21757993 0.98 MAPT (0.61) MAPTATMSMN1; SMN2RAD52ADRA2A
SCHEMBL9493787 0.92 MAPT (0.67) MAPTATMSMN1; SMN2RAD52ADRA2A
SCHEMBL11438133 0.88 SMN1; SMN2 (0.60) MAPTATMSMN1; SMN2RAD52MEN1
SCHEMBL9059747 0.87 MAPT (0.54) MAPTATMSMN1; SMN2RAD52ADRA2A
SCHEMBL151400 0.86 SMN1; SMN2 (0.58) MAPTATMSMN1; SMN2RAD52MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115646137-B Organic amine desulfurizing agent capable of effectively reducing foaming problem 北京北大先锋科技股份有限公司 2026-05-12 CN claimed
EP-4663277-A1 AMINE COMPOSITION FOR CARBON DIOXIDE SEPARATION AND METHOD FOR PRODUCING SAME Tosoh Corporation (JP) 2025-12-17 EP claimed
CN-119425311-A Purification method for efficiently removing degradation products of desthioamine liquid 河北精致科技有限公司 2025-02-14 CN claimed
WO-2024166977-A1 AMINE COMPOSITION FOR CARBON DIOXIDE SEPARATION AND METHOD FOR PRODUCING SAME 東ソー株式会社 2024-08-15 WO claimed
CN-114797469-B Organic amine desulfurization and desorption accelerator and preparation method and application thereof 双盾环境科技有限公司 2024-04-16 CN claimed
CN-115052637-B Deodorant agent 东曹株式会社 2024-03-01 CN claimed
US-20230356182-A1 COMPOSITION FOR CARBON DIOXIDE SEPARATION AND METHOD FOR SEPARATING CARBON DIOXIDE TOSOH CORPORATION (JP) 2023-11-09 US claimed
CN-112316669-B Organic amine desulfurizing agent and preparation method and application thereof 合肥工业大学 2023-06-23 CN claimed
US-20230059218-A1 DEODORANT TOSOH CORPORATION (JP) 2023-02-23 US claimed
CN-115646137-A Organic amine desulfurizer capable of effectively reducing foaming problem 北京北大先锋科技股份有限公司 2023-01-31 CN claimed
EP-1863475-A2 NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2007-12-12 EP claimed
EP-1863787-A1 HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS Actelion Pharmaceuticals Ltd. (CH) 2007-12-12 EP claimed
EP-1863474-A1 NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2007-12-12 EP claimed
WO-2007046075-A1 PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2007-04-26 WO claimed
WO-2006137019-A1 NOVEL THIOPHENE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-12-28 WO claimed
WO-2006100631-A1 HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2006-09-28 WO claimed
WO-2006100633-A1 NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2006-09-28 WO claimed
WO-2006100635-A2 NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2006-09-28 WO claimed
WO-2002092578-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2002-11-21 WO claimed
WO-2002092577-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2002-11-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230059218-A1 DEODORANT DAO, DDO, DDAH1 MAPT 2505/4885ATM 4216/4885SMN1; SMN2 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.